Smartinhaler developer Adherium Limited has announced that Thomas Lynch has been appointed the company’s new Chairman and that Doug Wilson will step down from the board to take on the role of Medical Director on a part time basis.
Lynch recently retired from his role as Chair of ICON after serving on that company’s board for over 20 years. He currently serves as Chair of Evofem Biosciences and Profectus Biosciences and as a non-executive director of GW Pharma.
The company said that Adherium’s recent expansion makes this “a logical time for Dr Wilson to move from the Board to free the Chair role for the new major international candidate.” In the past year, the company has grown to 50 employees, has added offices in the US and UK, announced a new partnership with AstraZeneca, and raised A$35 million in an IPO.
Adherium CEO Garth Sutherland commented, “On behalf of the Adherium Board, we offer our sincere thanks to Dr Wilson for the major contribution he has made to Adherium’s growth over the last four years, and we warmly welcome Mr Thomas Lynch to the Adherium Board for our next major phase of growth.”
Read the Adherium press release.
